ArticleClinical cancer research : an official journal of the American Association for Cancer Research2019
Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer.
Abstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.
0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed
11.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 116 citations in OpenAlex.
- A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2021Trial
- Tepotinib in Non-Small-Cell Lung Cancer withThe New England journal of medicine · 2020Trial
- Oncogenic mutations in non-small cell lung cancer: from molecular mechanisms to clinical practice.Signal transduction and targeted therapy · 2026Review
- Research progress on resistance and mechanisms of c-Met inhibitors in treatingJournal of thoracic disease · 2026Review
- MYC contributes to targeted therapy resistance in lung cancers driven by MET exon 14-skipping alteration.NPJ precision oncology · 2026Article
- Precision Medicine in Treating Lung Cancer: A Narrative Review on Treatments Targeting Oncogenic Genetic Mutations.Cureus · 2026Review
- Targeting MET in non-small cell lung cancer brain metastases: from molecular mechanism to precision therapy.Journal of translational medicine · 2026Review
- Investigation of the Prevalence of Associated Genetic Mutations (Co-Mutations) in Patients with Actionable Driver Mutations in Lung Cancer: A Retrospective Study.Diagnostics (Basel, Switzerland) · 2026Article
- Association of MET gene polymorphisms with breast cancer risk in Nigerian patients: a case-control study.BMC cancer · 2026Article
- Deciphering molecular pathways in urological cancers: A gateway to precision therapeutics.Journal of advanced research · 2026Review
- Alternative splicing in cancer drug resistance: Mechanisms and therapeutic prospects (Review).Oncology reports · 2026Review
- Kinase Inhibitors for Targeted Cancer Therapy.Current topics in medicinal chemistry · 2026Review
- MET Exon 14 Skipping Mutation in NSCLC: From Genomic Discovery to Biomarker-Guided Therapeutic Innovation.Current drug targets · 2026Review
- PTEN loss and ERBB2/ERBB3-mediated AKT reactivation drive resistance to MET inhibition in MET-amplified hepatocellular carcinoma.Cellular oncology (Dordrecht, Netherlands) · 2025Article
- Mechanistic insights into MET exon 14 skipping mutations and their role in tumor progression.Biochemical Society transactions · 2025Review
- Evolving roles of MET as a therapeutic target in NSCLC and beyond.Nature reviews. Clinical oncology · 2025Review
- MET variants with activating N-lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation.Molecular oncology · 2025Article
- Responsiveness of different MET tumour alterations to type I and type II MET inhibitors.Clinical and translational medicine · 2025Article
- Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration.Cancer biology & medicine · 2025Article
- The expanding role of the receptor tyrosine kinase MET as a therapeutic target in non-small cell lung cancer.Cell reports. Medicine · 2025Review
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 2 institutions in 2 countries.
Ken Suzawa *Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-2463-9696
Michael Offin *Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-7959-3018
Daniel LuIntegrative Oncology, British Columbia Cancer Center, Vancouver, British Columbia, Canada.
Christopher KurzatkowskiDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Morana VojnicDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Roger S SmithDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Joshua K SabariThoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Huichun TaiDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Marissa MattarAnti-tumor Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York.
Inna KhodosAnti-tumor Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York.
Elisa de StanchinaAnti-tumor Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York.
Charles M RudinThoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-5204-3465
Mark G KrisThoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Maria E ArcilaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
William W LockwoodIntegrative Oncology, British Columbia Cancer Center, Vancouver, British Columbia, Canada.
Alexander DrilonThoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. ladanyim@mskcc.org drilona@mskcc.org somwarr@mskcc.org.
Marc LadanyiDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. ladanyim@mskcc.org drilona@mskcc.org somwarr@mskcc.org.
Romel SomwarDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. ladanyim@mskcc.org drilona@mskcc.org somwarr@mskcc.org.
Memorial Sloan Kettering Cancer Center · USBC Cancer Agency · CA
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MThe Role of Focal Oncogene Amplifications in Lung CancerP01CA129243 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Piro Lito · 2007 to 2026
$31.2MInvestigational Cancer Therapeutics Training Program (ICTTP)T32CA009207 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Omar Abdel-Wahab, Alexander Drilon · 1985 to 2026
$13.7MMSKCC Pilot Center for Precision Disease ModelingU54OD020355 · OD · SLOAN-KETTERING INST CAN RESEARCH · PI LOWE, SCOTT W., SOLIT, DAVID B. · 2015 to 2019
$9.9MNCI NIH HHS P01 CA129243NCI NIH HHS P30 CA008748NIH HHS U54 OD020355
Abstract
purposeEXPERIMENTAL
designWe examined clinical and genomic data from 113 patients with lung cancer with
resultsFive of 113 patients (4.4%) with
conclusions
Indexed as
AgedAnimalsCarcinoma, Non-Small-Cell LungCrizotinibDrug Resistance, NeoplasmErb-b2 Receptor Tyrosine KinasesErbB ReceptorsExonsFemaleGene Expression Regulation, NeoplasticHeterograftsHigh-Throughput Nucleotide SequencingHumansMaleMAP Kinase Kinase KinasesMiceCrizotinibEGFR protein, humanERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesErbB ReceptorsKRAS protein, humanMAP Kinase Kinase KinasesMET protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins c-metProto-Oncogene Proteins p21(ras)
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.